top of page

About CASC8

CASC8 is a Belgian regenerative medicine company developing the first autologous cardiac
stem-cell therapy designed to regenerate heart tissue damaged by cardiovascular disease.

​​Founded in 2016 by Prof. Dr. Marc Hendrikx —
senior cardiac surgeon and professor of regenerative medicine at UHasselt —
he company builds on more than two decades of clinical and scientific expertise supported by peer-reviewed publications and public research funding.

To date, over €5 million has been invested into the development of CASC technology through CEO funding and VLAIO grants.

The therapy is protected under EU Patent EP2258833B1.

Our Science

With over a decade of research and 100+ validated preclinical models, CASC therapy has demonstrated the ability to:

​

  • Improve heart function

  • Reduce infarct size

  • Regenerate functional, beating cardiac cells

  • Promote vascular repair

  • Enhance survival

Our Approach

  • 100% autologous — no risk of immune rejection

  • Minimally invasive cell harvesting

  • Clinically feasible and GMP-ready

  • Supported by robust preclinical data

​

Our goal: to advance this therapy into first-in-human trials, bringing true cardiac regeneration closer to patients worldwide.

Our Team

m_hendrikx_edited.jpg
Marc Hendrikx — CEO

Cardiothoracic Surgeon, Professor of Regenerative Medicine (UHasselt), Member of the COS Research Group

karen_hensen_edited.jpg
Karen Hensen, PhD —
Program Manager

Expert in Cell Therapy,
Quality & Regulatory Affairs

marc-de-keersmaeker_edited_edited.jpg
Marc De Keersmaeker — CFO

Business Strategy,
Financial Management,
Business Development

e_heeren_edited.jpg
Ellen Heeren, MSc —
Cell Biologist

Specializing in Cardiac Regenerative Medicine

Dirk_Groenewegen_edited.jpg
Dirk Groenewegen — CSO

Immuno-oncology,
IP Valuation & Licensing

caroline_de_bouver_edited.jpg
Caroline De Bouver —
Scientific Researcher

Expert in GMP Production

CASC8 brings together a multidisciplinary team with over a century of combined experience in cardiology, regenerative medicine, biomedical R&D, surgery, cell therapy,
financial management and strategic business development.

The CASC8 World-Class
Scientific Advisory Board

 Our team is guided by leaders in cardiology,
ensuring scientific rigor, ethical standards, and clinical excellence.

CASC8

©2025 by CASC8.

bottom of page